THNR vs. CNCR

Last updated Jun 4, 2026

THNR (Amplify Weight Loss Drug & Treatment ETF) and CNCR (Loncar Cancer Immunotherapy ETF) are both Health & Biotech Equities funds - THNR tracks the VettaFi Weight Loss Drug & Treatment Index while CNCR tracks the Loncar Cancer Immunotherapy Index. Both are passively managed. THNR charges 0.59%/yr vs 0.79%/yr for CNCR.

Performance

THNR vs. CNCR - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Amplify Weight Loss Drug & Treatment ETF (THNR) and Loncar Cancer Immunotherapy ETF (CNCR). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

THNR

• 1D: -0.50%
• 1M: -3.61%
• YTD: -5.67%
• 6M: -4.62%
• 1Y: 8.57%
• 3Y*: —
• 5Y*: —
• 10Y*: —

CNCR

• 1D: 0.00%
• 1M: 0.00%
• YTD: —
• 6M: —
• 1Y: —
• 3Y*: —
• 5Y*: —
• 10Y*: —

*Multi-year figures are annualized to reflect compound growth (CAGR)

THNR vs. CNCR - Yearly Performance Comparison

	2026 (YTD)
THNR Amplify Weight Loss Drug & Treatment ETF	-8.40%
CNCR Loncar Cancer Immunotherapy ETF	0.00%

THNR vs. CNCR - Sectors Allocation Comparison

Sectors	THNR	CNCR
Healthcare	97.7%	96.6%
Financial Services	0.9%	3.3%
Basic Materials	-	-
Communication Services	-	-
Consumer Cyclical	-	-
Consumer Defensive	-	-
Energy	-	-
Industrials	-	-
Real Estate	-	-
Technology	-	-
Utilities	-	-

Return for Risk

THNR vs. CNCR — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

THNR

THNR Risk / Return Rank: 17
THNR Sharpe Ratio Rank: 16
THNR Sortino Ratio Rank: 17
THNR Omega Ratio Rank: 16
THNR Calmar Ratio Rank: 18
THNR Martin Ratio Rank: 17

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

THNR vs. CNCR - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Amplify Weight Loss Drug & Treatment ETF (THNR) and Loncar Cancer Immunotherapy ETF (CNCR). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	THNR	CNCR	Difference
Sharpe ratio Return per unit of total volatility	0.45	—	—
Sortino ratio Return per unit of downside risk	0.77	—	—
Omega ratio Gain probability vs. loss probability	1.09	—	—
Calmar ratio Return relative to maximum drawdown	0.71	—	—
Martin ratio Return relative to average drawdown	1.62	—	—
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

Sharpe Ratios by Period

	THNR	CNCR	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	0.45	—	—
Sharpe Ratio (All Time) Calculated using the full available price history	-0.10	—	—

Drawdowns

THNR vs. CNCR - Drawdown Comparison

The maximum THNR drawdown since its inception was -32.51%, which is greater than CNCR's maximum drawdown of 0.00%. Use the drawdown chart below to compare losses from any high point for THNR and CNCR.

Drawdown Indicators

	THNR	CNCR	Difference
Max Drawdown Largest peak-to-trough decline	-32.51%	0.00%	-32.51%
Max Drawdown (1Y) Largest decline over 1 year	-12.06%	—	—
Current Drawdown Current decline from peak	-13.43%	0.00%	-13.43%
Average Drawdown Average peak-to-trough decline	-12.25%	0.00%	-12.25%
Ulcer Index Depth and duration of drawdowns from previous peaks	5.31%	—	—

Volatility

Volatility by Period

	THNR	CNCR	Difference
Volatility (1M) Calculated over the trailing 1-month period	5.16%	—	—
Volatility (6M) Calculated over the trailing 6-month period	13.37%	—	—
Volatility (1Y) Calculated over the trailing 1-year period	19.16%	0.00%	+19.16%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	19.35%	0.00%	+19.35%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	19.35%	0.00%	+19.35%

THNR vs. CNCR - Expense Ratio Comparison

THNR has a 0.59% expense ratio, which is lower than CNCR's 0.79% expense ratio.

Dividends

THNR vs. CNCR - Dividend Comparison

THNR's dividend yield for the trailing twelve months is around 1.74%, while CNCR has not paid dividends to shareholders.

Position	TTM	2025	2024
CNCR Loncar Cancer Immunotherapy ETF	0.00%	0.00%	0.00%
THNR Amplify Weight Loss Drug & Treatment ETF	1.74%	1.64%	0.98%

Frequently Asked Questions

Which ETF is better, THNR or CNCR?

On fees, THNR is cheaper at 0.59% per year. The better choice depends on whether you care most about return, fees, risk, or income.

Which ETF is cheaper, THNR or CNCR?

THNR is cheaper with a 0.59% expense ratio, compared with 0.79% for CNCR.

Which ETF pays a higher dividend yield, THNR or CNCR?

THNR has the higher dividend yield at 1.74%, compared with 0.00% for CNCR.

What is the main difference between THNR and CNCR?

THNR tracks VettaFi Weight Loss Drug & Treatment Index, while CNCR tracks Loncar Cancer Immunotherapy Index. They also come from different issuers: Amplify and Exchange Traded Concepts. Their fees differ too: 0.59% for THNR and 0.79% for CNCR.